Granisetron Prevents Postoperative Nausea at Low 0.1 mg Dose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

NEW YORK-New data suggests that granisetron (Kytril) can effectively prevents postoperative nausea and vomiting at doses as low as 0.1 mg. Robert D’Angelo, MD, Department of Anesthesiology, Wake Forest University, Baptist Medical Center, presented the study results at the 56th Annual Post Graduate Assembly in Anesthesiology.

NEW YORK—New data suggests that granisetron (Kytril) can effectively prevents postoperative nausea and vomiting at doses as low as 0.1 mg. Robert D’Angelo, MD, Department of Anesthesiology, Wake Forest University, Baptist Medical Center, presented the study results at the 56th Annual Post Graduate Assembly in Anesthesiology.

Granisetron is a selective, 5-hydroxy-tryptamine type 3 (5-HT3) receptor antagonist class of antiemetic. It is approved for intravenous use to prevent and treat postoperative nausea and vomiting at a dosage of 1 mg, and is also approved for the prevention of chemotherapy- and radiation-induced nausea and vomiting.

In this multicenter, randomized, double-blind, dose-ranging pilot study, 121 patients undergoing abdominal hysterectomy requiring general anesthesia received a single granisetron dose intravenously. The agent proved more effective than placebo at doses of 0.1 mg, 0.2 mg, and 0.3 mg, and was similar to the efficacy of other 5-HT3-receptor antagonists.

No Vomiting in More Than 90%

The percentages of patients with no vomiting up to 6 hours after drug administration were 94%, 96%, 91%, and 77% for granisetron 0.1 mg, 0.2 mg, 0.3 mg, and placebo, respectively. The percentages of patients with total control (no vomiting, no moderate-to-severe nausea, and no use of rescue medication over 0 to 6 hours) were 65%, 56%, 67%, and 33%, respectively. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video